The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens. Havrilesky LJ, Scott AL, Davidson BA, Secord AA, et al. Gynecol Oncol 2021 May 27. pii: S0090-8258(21)00428.

Read + Share

Amedeo Smart

Independent Medical Education

Havrilesky LJ, Scott AL, Davidson BA, Secord AA, et al. The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens. Gynecol Oncol 2021 May 27. pii: S0090-8258(21)00428.
PMID: 34053748